Aroa Biosurgery Ltd

As of March 31, 2026, Aroa Biosurgery Ltd. carries a market capitalization of 175.41M, placing it among publicly traded companies globally. Its enterprise value stands at 163.51M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Aroa Biosurgery Ltd.'s next confirmed earnings release is scheduled for November 26, 2026.

As of March 31, 2026, Aroa Biosurgery Ltd. has 345.48M shares outstanding.

As of March 31, 2026, Aroa Biosurgery Ltd. trades at a trailing price-to-earnings ratio of 65.11. The price-to-sales ratio is 2.93, and the price-to-book ratio stands at 3.07.

As of March 31, 2026, Aroa Biosurgery Ltd. trades at an EV/EBITDA multiple of 61.36 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.74 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 163.51M versus a market cap of 175.41M, with the gap driven by net debt and cash on the balance sheet.

As of March 31, 2026, Aroa Biosurgery Ltd. maintains a current ratio of 4.77, meaning it holds 4.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.42, indicating elevated leverage, while an interest coverage ratio of 3.36 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended March 31, 2026, Aroa Biosurgery Ltd. posted a return on equity (ROE) of 4.66, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -0.52, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 3.91, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.51, useful for judging operating efficiency across full business cycles. Inventory turnover of 2.00 indicates how many times Aroa Biosurgery Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2026, Aroa Biosurgery Ltd. recorded 342,437.20 in income tax expense. That works out to an effective tax rate of 11.28, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 3.03M, leaving 2.69M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on September 11, 2026, Aroa Biosurgery Ltd.'s stock has gained approximately 35.03% over the past 52 weeks.

Over the twelve months ended March 31, 2026, Aroa Biosurgery Ltd. generated 59.77M in revenue and converted that into 2.69M in net income, yielding earnings per share of 0.01. EBITDA reached 2.66M, while operating income came in at -358,551.89.

As of March 31, 2026, Aroa Biosurgery Ltd. holds 15.57M in cash and equivalents against 3.67M in total debt, resulting in a net debt position of -12.12M. Total book value stands at 57.17M, with working capital of 35.15M providing operational flexibility.

These figures cover the twelve months ended March 31, 2026.

Over the twelve months ended March 31, 2026, Aroa Biosurgery Ltd. posted a gross margin of 85.53, reflecting its pricing power and cost economics. The operating margin of -0.60 and net profit margin of 4.50 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2026. Total shareholder yield reaches 0.57, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Aroa Biosurgery Ltd. shareholders.

As of March 31, 2026, Aroa Biosurgery Ltd. has an Altman Z-Score of 9.57, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.